62 related articles for article (PubMed ID: 38577439)
1. Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report.
Pendry SD; Singhal N; Neo EL; Foreman D; Winter JM
Clin Case Rep; 2024 Jun; 12(6):e8929. PubMed ID: 38799519
[TBL] [Abstract][Full Text] [Related]
2. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
3. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma.
Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz-Osuna S; Fabregat J
Surg Oncol; 2024 Feb; 52():102027. PubMed ID: 38113726
[TBL] [Abstract][Full Text] [Related]
4. Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma.
Xia DQ; Zhou Y; Yang S; Li FF; Tian LY; Li YH; Xu HY; Xiao CZ; Wang W
World J Gastrointest Oncol; 2024 Mar; 16(3):798-809. PubMed ID: 38577439
[TBL] [Abstract][Full Text] [Related]
5. Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy.
Yang HK; Park MS; Han K; Eom G; Chung YE; Choi JY; Bang S; Kang CM; Seong J; Kim MJ
Cancer Res Treat; 2024 Jan; 56(1):247-258. PubMed ID: 37605535
[TBL] [Abstract][Full Text] [Related]
6. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
7. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
8. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients.
Wang K; Karalis JD; Elamir A; Bifolco A; Wachsmann M; Capretti G; Spaggiari P; Enrico S; Balasubramanian K; Fatimah N; Pontecorvi G; Nebbia M; Yopp A; Kaza R; Pedrosa I; Zeh H; Polanco P; Zerbi A; Wang J; Aguilera T; Ligorio M
Ann Surg Oncol; 2024 Apr; 31(4):2608-2620. PubMed ID: 38151623
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized Study.
Chiu YF; Liu TW; Shan YS; Chen JS; Li CP; Ho CL; Hsieh RK; Hwang TL; Chen LT; Ch'ang HJ;
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):74-86. PubMed ID: 37055279
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.
Kane LE; Mellotte GS; Mylod E; O'Brien RM; O'Connell F; Buckley CE; Arlow J; Nguyen K; Mockler D; Meade AD; Ryan BM; Maher SG
Cancer Res Commun; 2022 Oct; 2(10):1229-1243. PubMed ID: 36969742
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy for pancreatic cancer.
Springfeld C; Ferrone CR; Katz MHG; Philip PA; Hong TS; Hackert T; Büchler MW; Neoptolemos J
Nat Rev Clin Oncol; 2023 May; 20(5):318-337. PubMed ID: 36932224
[TBL] [Abstract][Full Text] [Related]
13. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer.
Balaban DV; Marin FS; Manucu G; Zoican A; Ciochina M; Mina V; Patoni C; Vladut C; Bucurica S; Costache RS; Ionita-Radu F; Jinga M
World J Clin Oncol; 2022 Jul; 13(7):630-640. PubMed ID: 36157158
[TBL] [Abstract][Full Text] [Related]
15. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Hamad A; Crossnohere N; Ejaz A; Tsung A; Pawlik TM; Sarna A; Santry H; Wills C; Cloyd JM
Pancreas; 2022 Jul; 51(6):657-662. PubMed ID: 36099500
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
